{"atc_code":"B01","metadata":{"last_updated":"2021-02-09T23:35:37.312707Z","applied_components":{"decision_date_extraction":{"output_fields":["attachment.decision_date"],"input_checksum":"f336b21f17bdbcfc74c5f49abbcce54162c9017178a5ee9ba10e465e20f90ce9","last_success":"2021-02-10T05:03:19.988904Z","output_checksum":"f429f64808d84b4b08098bf403595a8de2439affb9624c54bcfd025793addffd","success":true,"name":"decision_date_extraction","input_fields":["attachment.type","attachment.content"],"version":1,"finish_time":"2021-02-10T05:03:19.988904Z","status":"NOT_APPLICABLE"},"study-ids-enricher":{"output_fields":["attachment.studies","attachment.max_study_phase"],"input_checksum":"b987da12b32d984cbf3457083b83a5dc832cd82817286e2293450d3fa7ac73db","last_success":"2021-02-09T23:38:23.638500Z","output_checksum":"f429f64808d84b4b08098bf403595a8de2439affb9624c54bcfd025793addffd","success":true,"name":"study-ids-enricher","input_fields":["attachment.type","active_substance","attachment.content"],"version":28,"finish_time":"2021-02-09T23:38:23.638500Z","status":"NOT_APPLICABLE"},"EmaDataAccessor":{"output_fields":[],"input_checksum":"44136fa355b3678a1146ad16f7e8649e94fb4fc21fe77e8310c060f61caaff8a","last_success":"2021-02-09T23:35:37.312705Z","output_checksum":"44136fa355b3678a1146ad16f7e8649e94fb4fc21fe77e8310c060f61caaff8a","success":true,"name":"EmaDataAccessor","input_fields":[],"version":3,"finish_time":"2021-02-09T23:35:37.312705Z","status":"UP_TO_DATE"},"historic_pivotal_studies":{"output_fields":["attachment.historic_pivotal_studies"],"input_checksum":"f429f64808d84b4b08098bf403595a8de2439affb9624c54bcfd025793addffd","last_success":"2021-02-10T05:00:30.590583Z","output_checksum":"f429f64808d84b4b08098bf403595a8de2439affb9624c54bcfd025793addffd","success":true,"name":"historic_pivotal_studies","input_fields":["attachment.studies.study_ids"],"version":2,"finish_time":"2021-02-10T05:00:30.590583Z","status":"UP_TO_DATE"},"section_ranges_extraction":{"output_fields":["attachment.labelSections"],"input_checksum":"f336b21f17bdbcfc74c5f49abbcce54162c9017178a5ee9ba10e465e20f90ce9","last_success":"2021-02-10T05:02:46.513633Z","output_checksum":"f429f64808d84b4b08098bf403595a8de2439affb9624c54bcfd025793addffd","success":true,"name":"section_ranges_extraction","input_fields":["attachment.type","attachment.content"],"version":2,"finish_time":"2021-02-10T05:02:46.513633Z","status":"UP_TO_DATE"},"prime_designation_enricher":{"output_fields":["prime_designation"],"input_checksum":"f336b21f17bdbcfc74c5f49abbcce54162c9017178a5ee9ba10e465e20f90ce9","last_success":"2021-02-10T17:00:06.736049Z","output_checksum":"dcf4d2ed94fa29974e643bd4a70cd26ec785f1130958f3e23e8022193699a97a","success":true,"name":"prime_designation_enricher","input_fields":["attachment.type","attachment.content"],"version":3,"finish_time":"2021-02-10T17:00:06.736049Z","status":"UP_TO_DATE"},"AttachmentDownloader":{"output_fields":[],"last_failure":"2021-02-11T17:00:06.850609Z","success":false,"name":"AttachmentDownloader","input_fields":[],"error":"java.lang.RuntimeException: 500 : [{\"timestamp\":1613062806848,\"status\":500,\"error\":\"Internal Server Error\",\"message\":\"\",\"path\":\"/downloadAndExtract\"}]","version":2,"finish_time":"2021-02-11T17:00:06.850609Z","status":"FAILURE"},"rapporteur_extraction":{"output_fields":["attachment.co_rapporteur","attachment.main_rapporteur"],"input_checksum":"f336b21f17bdbcfc74c5f49abbcce54162c9017178a5ee9ba10e465e20f90ce9","last_success":"2021-02-10T11:00:31.682824Z","output_checksum":"f429f64808d84b4b08098bf403595a8de2439affb9624c54bcfd025793addffd","success":true,"name":"rapporteur_extraction","input_fields":["attachment.type","attachment.content"],"version":2,"finish_time":"2021-02-10T11:00:31.682824Z","status":"NOT_APPLICABLE"}},"agency":"EMA","product_id":"1F11DCA6901AD646A9ECBDC3A3034439","direct_link":"https://www.ema.europa.eu/en/medicines/human/EPAR/kengrexal","first_created":"2021-02-09T23:35:37.146625Z","component_failures":{"AttachmentDownloader":"java.lang.RuntimeException: 500 : [{\"timestamp\":1613062806848,\"status\":500,\"error\":\"Internal Server Error\",\"message\":\"\",\"path\":\"/downloadAndExtract\"}]"}},"revision_number":9,"approval_status":"authorised","active_substance":"cangrelor","additional_monitoring":true,"inn":"cangrelor","prime_designation":false,"accelerated_assessment":false,"orphan":false,"product_name":"Kengrexal","authorization_holder":"Chiesi Farmaceutici S.p.A.","generic":false,"product_number":"EMEA/H/C/003773","initial_approval_date":"2015-03-23","attachment":[{"link":"https://www.ema.europa.eu/documents/product-information/kengrexal-epar-product-information_en.pdf","id":"37773269B7E0669210CDDD962C3B146B","type":"productinformation","title":"Kengrexal : EPAR - Product Information"}],"conditional_approval":false,"exceptional_circumstances":false,"indication":"<div> \n <div class=\"ecl-field__body\"> \n  <div class=\"ecl-editor first last\">\n   <p>Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable.</p>\n  </div> \n </div> \n</div>","therapeutic_area":["Acute Coronary Syndrome","Vascular Surgical Procedures"],"contact_address":"Via Palermo 26/A\n43122 Parma\nItaly","biosimilar":false}